| Milwaukee Otologic Auditory Rehabilitation Services Ltd. | |
|
11035 W Forest Home Ave, Suite 108, Hales Corners, WI 53130-2541 | |
| (414) 529-3215 | |
| (414) 529-3214 |
| Full Name | Milwaukee Otologic Auditory Rehabilitation Services Ltd. |
|---|---|
| Type | Facility |
| Speciality | Clinic/center - Hearing And Speech |
| Location | 11035 W Forest Home Ave, Hales Corners, Wisconsin |
| Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134243967 | NPI | - | NPPES |
| 41171700 | Medicaid | WI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 231H00000X | Audiologist | (* (Not Available)) | Secondary |
| 261QH0700X | Clinic/center - Hearing And Speech | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Milwaukee Otologic Auditory Rehabilitation Services Ltd. 11035 W Forest Home Ave, Suite 108, Hales Corners, WI 53130-2541 Ph: (414) 529-3215 | Milwaukee Otologic Auditory Rehabilitation Services Ltd. 11035 W Forest Home Ave, Suite 108, Hales Corners, WI 53130-2541 Ph: (414) 529-3215 |
News Archive
Scancell Holdings Plc, the developer of therapeutic cancer vaccines, announces that a treatment utilising a DNA vaccine based on its ImmunoBody® technology, in combination with ImmuneRegen BioSciences, Inc.®'s lead compound, Homspera®, has significantly improved the immune response of the vaccine in an animal model. Follow-up studies are currently being performed to optimize the effects of Homspera in enhancing the next generation of Scancell's cancer vaccines.
Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today that a combination of its synthetic consensus H1N1, H2N2, H3N2, and H5N1 influenza vaccine candidates achieved protective antibody responses against several different influenza sub-types and strains in ferrets.
"[T]he highest levels ever of drug-resistant tuberculosis (TB) have been found in Russia and Moldova," the WHO reports in research published in the February edition of the WHO Bulletin, but "the agency didn't have data from most of Africa and India, where tuberculosis rates are much higher," the Associated Press/USA Today's "Your Life" reports.
BioTime, Inc. today announced that it has elected to market progenitors of muscle stem cells bearing hereditary diseases. BioTime will produce the products from five human embryonic stem (hES) cell lines from Reproductive Genetics Institute (RGI) of Chicago, Illinois.
K7 LLC's K7C Cervical Spacer, a spinal implant device using Evonik's VESTAKEEP PEEK (polyetheretherketone), has received the U.S. Food and Drug Administration's (FDA) 510(k) approval for use as an Intervertebral Body Fusion (IBF) device.
› Verified 4 days ago